Sanofi Rare Disease has created an opportunity for healthcare professionals to come together to review and discuss the recent publication Safety and Efficacy of Avalglucosidase alfa vs. Alglucosidase alfa in Patients with Late-onset Pompe disease (COMET): A Phase 3, Randomized, Multicentre Trial. Please see the attached invitation and link to register. We are also including the information below.
When: Wednesday, December 8th 2022 @7pm
Presented by: David Kronn, MD
Registration via: Webinar Registration – Zoom
Once you have registered, you will receive an email from Sanofi Genzyme Virtual Events that contains the participant link for the day of the program. You can add it to your calendar by following the prompts contained in that email. Additionally, once we know of your intention to participate, we will send you an email with background information and the link to the journal article. We are looking forward to your attendance and a robust discussion.
Please let us know if you have any difficulty registering. We would be glad to assist.